Jennifer M Matro, MD

faculty photo
Assistant Professor of Clinical Medicine
Department: Medicine

Contact information
Division of Hematology Oncology
Perelman Center for Advanced Medicine
10th Floor, South Pavilion
Office #10-102
3400 Civic Center Blvd
Philadelphia, PA 19104
Office: 215-662-7096
Fax: 215-615-3349
Education:
BA (Public Policy Studies/Health Policy Certificate)
Duke University, Durham NC, 2003.
MD
University of Pennsylvania School of Medicine, 2008.
Permanent link
 
> Perelman School of Medicine   > Faculty   > Details

Selected Publications

Boland P M, Ruth K, Matro J M, Rainey K L, Fang C Y, Wong Y N, Daly M B, Hall M J: Genetic counselors' (GC) knowledge, awareness, understanding of clinical next-generation sequencing (NGS) genomic testing. Clinical Genetics 88(6): 565-72, Dec 2015.

Matro JM, Li T, Cristofanilli M, Hughes ME, Ottesen RA, Weeks JC, Wong YN.: Inflammatory Breast Cancer Management in the National Comprehensive Cancer Network: The Disease, Recurrence Pattern, and Outcome. Clinical Breast Cancer 15(1): 1-7, Feb 2015.

Martei Yehoda M, Matro Jennifer M: Identifying patients at high risk of breast cancer recurrence: strategies to improve patient outcomes. Breast cancer (Dove Medical Press) 7: 337-43, 2015.

Matro JM, Ruth KJ, Wong YN, McCully KC, Rybak CM, Meropol NJ, Hall MJ.: Cost Sharing and Hereditary Cancer Risk: Predictors of Willingness-to-Pay for Genetic Testing. Journal of Genetic Counseling 23(6): 1002-11, Dec 2014.

Matro JM, Walia R, Tumelty K, Morrison T, Goldstein LJ: Bilateral Hypoglossal Nerve Palsy Due to Breast Cancer Skull Base Metastases. American Journal of Hematology and Oncology 10(5): 22-24, November 2014.

Matro JM, Yu JQ, Heinrich MC, Ramachandran A, Ku N, vonMehren M: Correlation of PET/CT and CT RECIST Response in GIST Patients with PDGFRA D842V Gene Mutations Treated with Crenolanib. J Clin Oncol 32:5s (suppl; abstr 10546), May 30-June 3 2014 Notes: Poster presentation.

Matro JM and Goldstein LJ: How do I follow patients with early breast cancer after completing adjuvant therapy. Current Treatment Options in Oncology 15(1): 63-78, March 2014.

Matro JM, Ruth RJ, Wong YN, McCully KC, Rybak CM, Hall MJ: Cost sharing and hereditary cancer risk: Predictors of willingness-to-pay for genetic testing. Pennsylvania Society of Oncology and Hematology annual meeting, Harrisburg, PA September 21-22 2012 Notes: Oral presentation.

Matro JM, Ruth KJ, Wong YN, McCully KC, Rybak CM, Hall MJ: Cost sharing and hereditary cancer risk: Predictors of willingness-to-pay for genetic testing. J Clin Oncol 30 (suppl; abstr 1544), June 1-5 2012 Notes: Poster presentation.

Su HI, Sammel MD, Green JA, Velders L, Stankiewicz C, Matro JM, Freeman EW, Garcia CR, DeMichele AD: Anti-mullerian hormone and inhibin B are hormone measures of ovarian function in late reproductive-aged breast cancer survivors. Cancer 116(3): 592-9, 2010.

back to top
Last updated: 10/16/2017
The Trustees of the University of Pennsylvania